BMS-303141

• Background:

  Potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 M. Inhibits lipid biosynthesis, IC50=8 M in HepG2 cells.1,2 Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2 A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2 Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3 Reduces cell cycle progression in iBN cells.4

• Conjugation:

  Unconjugated

• Buffer:

  White solid

• Storage Conditions:

  -20°C